Status:
COMPLETED
Comparative Study Between Rezum and Tamsulosin
Lead Sponsor:
khaled Abdelsattar Gad Ibrahim
Conditions:
Prostate Hyperplasia
Eligibility:
MALE
50-80 years
Phase:
NA
Brief Summary
the investigators aimed to compare the efficacy and safety of Rezūm therapy for the management of benign prostatic hyperplasia (BPH) with Tamsulosin.
Detailed Description
So far, data from available studies point towards good clinical outcomes with a short-term risk of self-limiting minor complications. Its application has demonstrated clinical effectiveness and posses...
Eligibility Criteria
Inclusion
- with prostate volumes of 30- 80 mL,
- mild to mod LUTS
- (maximum urinary flow rate \[Q max\] of \<15 mL/s
- International Prostate Symptom Score \[IPSS\] of \>13)
- PVR urine \< 250 ml
Exclusion
- prostate cancer,
- neurogenic bladder
- urethral stricture,
- urinary bladder stone
- previous prostatic surgery
Key Trial Info
Start Date :
May 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2023
Estimated Enrollment :
94 Patients enrolled
Trial Details
Trial ID
NCT07169773
Start Date
May 1 2022
End Date
June 1 2023
Last Update
September 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Armed Forces College of Medicine (AFCM
Cairo, Nozha, Egypt, 4470351